We will be presenting at the Pharmaceutical & BioScience Society - San Francisco Bay Luncheon on July 28, 2017 at the SF Bay Area: Foster City Crown Plaza
Developing Relevant Human Neural In Vitro Assays for CNS Safety Assessment and Drug Discovery: Challenges and Perspectives
About the Topic
High attrition rates of novel CNS drugs indicate that current preclinical testing is largely insufficient to support development of urgently needed therapies for millions of patients. iPSC technology and rapidly improving methods to generate functional human tissues offer new opportunities to develop novel disease relevant cell-based assays. This approach comes with high expectations but also presents many challenges. NeuCyte develops human neural in vitro platforms uniquely suited for assessing relevant complex electrophysiology readouts allowing for more reliable prediction of drug efficacy, CNS safety, and identification of neurotoxicity. In this presentation, we will provide an overview of critical considerations that need to be taken when developing human iPSC derived neural in vitro assays.